Antioxidant nutrients protect against cyclosporine A nephrotoxicity

Toxicology

Volumn 189, Issue 1-2, 2003, Pages 99-111

  Parra Cid, T ^a   Conejo Garcia J R ^a   Carballo Alvarez F ^a,b   De Arriba, G ^a,b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Cyclosporine A; Eicosanoids; Free radicals; Lipid peroxidation; Reactive oxygen species; Thiobarbituric acid reactive substances (TBARS); Thromboxane; Vitamin E

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; AZATHIOPRINE; CALCIUM ANTAGONIST; CYCLOSPORIN A; GENTAMICIN; GLYCEROL; ICOSANOID; LACIDIPINE; LAZAROID; MALONALDEHYDE; MELATONIN; NICOTINIC ACID; PANTOTHENIC ACID; PROSTACYCLIN; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SELENIUM; TACROLIMUS; THIAMINE; THROMBOXANE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; GRAFT REJECTION; HUMAN; KIDNEY FUNCTION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

EID: 0038749553     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(03)00156-2     Document Type: Review

References (77)

1. Adhirai M., Selvam R. Effect of cyclosporin on liver antioxidants and the protective role of vitamin E in hyperoxaluria in rats. J. Pharm. Pharmacol. 50:1998;501-505.
2. Ahmed S.S., Strobel H.W., Napoli K.L., Grevel J. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. J. Pharmacol. Exp. Ther. 265:1993;1047-1054.
3. Apanay D.C., Neylan J.F., Ragab M.S., Sgoutas D.S. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. 58:1994;663-669.
4. Barros E.J., Boim M.A., Ajzen H., Ramos O.L., Schor N. Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int. 32:1987;19-25.
5. Baud L., Ardaillou R. Reactive oxygen species: production and role in the kidney. Am. J. Physiol. 251:1986;F765-F776.
6. Bennett W.M., Porter G.A. Cyclosporine-associated hypertension. Am. J. Med. 85:1988;131-133.
7. Berkenboom G., Brekine D., Fang Z.Y., Neve J., Fontaine J. Prevention by selenium supplementation of cyclosporin-A-induced vascular toxicity. Cardiovasc. Res. 33:1997;650-654.
8. Berliner J.A., Territo M.C., Sevanian A., Ramin S., Kim J.A., Bamshad B., Esterson M., Fogelman A.M. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85:1990;1260-1266.
9. Berty R.M., Adler S. In vivo and in vitro rat model for cyclosporine-induced proximal tubular toxicity. J. Lab. Clin. Med. 118:1991;17-25.
10. Beveridge T. White D.J.G. Cyclosporine A: Proceedings of an International Conference on Cyclosporine A. 1982;35-44 Elsevier Biomedical Press, Amsterdam.
11. Borel J.F. Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology. 31:1976;631-641.
12. Borel J.F., Feurer C., Gubler H.U., Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent 1976. Agents Actions. 43:1976;179-186.
13. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.L., Bach J.F. Factors associated with early remission of type I diabetes in children treated with cyclosporine. New Engl. J. Med. 318:1988;663-670.
14. Boyd H.C., Gown A.M., Wolfbauer G., Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am. J. Pathol. 135:1989;815-825.
15. Brown Z., Neild G.H., Lewis G.P. Inhibition of prostacyclin formation by cyclosporin is not due to reduced availability of arachidonic acid in membrane phospholipids of cultured human endothelial cells. Biochem. Pharmacol. 39:1990;1136-1138.
16. Calne R.Y., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Pentlow B.D., Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323-1327.
17. Calne R.Y., Rolles K., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Henderson R.G., Aziz S., Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 2:1979;1033-1036.
18. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94:1993;350-356.
19. Citterio F., Kahan B.D. The inhibitory effect of cyclosporine on the nuclear proliferative response to a variety of T cell activators. Transplantation. 47:1989;334-338.
20. Coffman T.M., Ruiz P., Sanfilippo F., Klotman P.E. Chronic thromboxane inhibition preserves function of rejecting rat renal allografts. Kidney Int. 35:1989;24-30.
21. Cristol J.P., Vela C., Maggi M.F., Descomps B., Mourad G. Oxidative stress and lipid abnormalities in renal transplant recipients with or without chronic rejection. Transplantation. 65:1998;1322-1328.
22. de Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306.
23. dos Santos O.F., Boim M.A., Barros E.J., Pirotzky E., Braquet P., Schor N. Nephrotoxicity of cyclosporine: the role of platelet-activating factor and thromboxane. Lipids. 26:1991;1320-1323.
24. Durak I., Karabacak H.I., Buyukkocak S., Cimen M.Y., Kacmaz M., Omeroglu E., Ozturk H.S. Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine. Protective effects of vitamins E and C. Nephron. 78:1998;207-211.
25. Durkan A.M., Hodson E.M., Willis N.S., Craig J.C. Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. Kidney Int. 59:2001;1919-1927.
26. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., Billings J.K., Brown M.D., Headington J.T., Cooper K.D., Baadsgaard O., Duell E.A., Annesley T.M., et al. Cyclosporine improves psoriasis in a double-blind study. J. Am. Med. Assoc. 256:1986;3110-3116.
27. English J., Evan A., Houghton D.C., Bennett W.M. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation. 44:1987;135-141.
28. Erlanger B.F. Do we know the site of action of cyclosporin. Immunol. Today. 13:1992;487-490.
29. Erlanger B.F. Why cyclosporin is an effective drug. Immunol. Today. 14:1993;369.
30. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl. Acad. Sci. USA. 77:1980;2214-2218.
31. Forre O., Bjerkhoel F., Salvesen C.F., Berg K.J., Rugstad H.E., Saelid G., Mellbye O.J., Kass E. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum. 30:1987;88-92.
32. Ghanem H., van den Dorpel M.A., Weimar W., Man in T.V.A.J., El-Kannishy M.H., Jansen H. Increased low density lipoprotein oxidation in stable kidney transplant recipients. Kidney Int. 49:1996;488-493.
33. Graham R.M. Cyclosporine: mechanisms of action and toxicity. Clevel. Clin. J. Med. 61:1994;308-313.
34. Greene E.L., Paller M.S. Oxygen free radicals in acute renal failure. Miner. Electrolyte Metab. 17:1991;124-132.
35. Harding M.W., Handschumacher R.E., Speicher D.W. Isolation and amino acid sequence of cyclophilin. J. Biol. Chem. 261:1986;8547-8555.
36. High K.P. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation. 57:1994;1689-1700.
37. Horina J.H., Wirnsberger G.H., Kenner L., Holzer H., Krejs G.J. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation. 56:1993;1091-1094.
38. Inselmann G., Hannemann J., Baumann K. Cyclosporine A induced lipid peroxidation and influence on glucose-6-phosphatase in rat hepatic and renal microsomes. Res. Commun. Chem. Pathol. Pharmacol. 68:1990;189-203.
39. Kahan B.D. Cyclosporine. New Engl. J. Med. 321:1989;1725-1738.
40. Kahan B.D., Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation. 46:1988;631-644.
41. Kim S.Y., Kim C.H., Yoo H.J., Kim Y.K. Effects of radical scavengers and antioxidant on ischemic acute renal failure in rabbits. Renal Fail. 21:1999;1-11.
42. Krysztopik R.J., Bentley F.R., Spain D.A., Wilson M.A., Garrison R.N. Lazaroids prevent acute cyclosporine-induced renal vasoconstriction. Transplantation. 63:1997;1215-1220.
43. Kumar K.V., Naidu M.U., Shifow A.A., Prayag A., Ratnakar K.S. Melatonin: an antioxidant protects against cyclosporine-induced nephrotoxicity. Transplantation. 67:1999;1065-1068.
44. L'Azou B., Medina J., Frieauff W., Cordier A., Cambar J., Wolf A. In vitro models to study mechanisms involved in cyclosporine A-mediated glomerular contraction. Arch. Toxicol. 73:1999;337-345.
45. Mason J. The pathophysiology of Sandimmune (cyclosporine) in man and animals. Pediatr. Nephrol. 4:1990;686-704.
46. Masuda A., Longo D.L., Kobayashi Y., Appella E., Oppenheim J.J., Matsushima K. Induction of mitochondrial manganese superoxide dismutase by interleukin 1. FASEB J. 2:1988;3087-3091.
47. Mihatsch M.J., Thiel G., Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant. Proc. 20:1988;759-771.
48. Morel D.W., Hessler J.R., Chisolm G.M. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J. Lipid Res. 24:1983;1070-1076.
49. Naidu M.U., Kumar K.V., Shifow A.A., Prayag A., Ratnakar K.S. Lacidipine protects against cyclosporine-induced nephrotoxicity in rats. Nephron. 81:1999;60-66.
50. Nath K.A., Norby S.M. Reactive oxygen species and acute renal failure. Am. J. Med. 109:2000;665-678.
51. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am. J. Ophthalmol. 96:1983;275-282.
52. Parra T., de Arriba G., Arribas I., Pérez de Lema G., Rodríguez-Puyol D., Rodríguez-Puyol M. Cyclosporine A nephrotoxicity: role of thromboxane and reactive oxygen species. J. Lab. Clin. Med. 131:1998;63-70.
53. Parra T., de Arriba G., Conejo J.R., Cantero M., Arribas I., Rodríguez-Puyol D., Rodríguez-Puyol M., Carballo F. Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity. Transplantation. 66:1998;1325-1329.
54. Penn I. Cancers following cyclosporine therapy. Transplantation. 43:1987;32-35.
55. Perez de Lema G., Arribas I., Prieto A., Parra T., de Arriba G., Rodriguez-Puyol D., Rodriguez-Puyol M. Cyclosporin A-induced hydrogen peroxide synthesis by cultured human mesangial cells is blocked by exogenous antioxidants. Life Sci. 62:1998;1745-1753.
56. Perico N., Benigni A., Zoja C., Delaini F., Remuzzi G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am. J. Physiol. 251:1986;F581-F587.
57. Pickrell M.D., Sawers R., Michael J. Pregnancy after renal transplantation: severe intrauterine growth retardation during treatment with cyclosporin A. Br. Med. J. (Clin. Res. Ed.). 296:1988;825.
58. Ptachcinski R.J., Burckart G.J., Venkataramanan R. Cyclosporine. Drug Intell. Clin. Pharm. 19:1985;90-100.
59. Rabl H., Khoschsorur G., Colombo T., Petritsch P., Rauchenwald M., Koltringer P., Tatzber F., Esterbauer H. A multivitamin infusion prevents lipid peroxidation and improves transplantation performance. Kidney Int. 43:1993;912-917.
60. Ruiz P., Coffman T.M., Klotman P.E., Sanfilippo F. Association of chronic thromboxane inhibition with reduced in situ cytotoxic T cell activity in rejecting rat renal allografts. Transplantation. 48:1989;660-666.
61. Schnabel F.R., Wait R.B., Kahng K.U. The relationship of urinary thromboxane excretion to cyclosporine nephrotoxicity. Transplantation. 51:1991;686-689.
62. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
63. Selvam R., Adhirai M. Vitamin E pretreatment prevents cyclosporin A-induced crystal deposition in hyperoxaluric rats. Nephron. 75:1997;77-81.
64. Showstack J., Katz P., Amend W., Bernstein L., Lipton H., O'Leary M., Bindman A., Salvatierra O. The effect of cyclosporine on the use of hospital resources for kidney transplantation. New Engl. J. Med. 321:1989;1086-1092.
65. Tariq M., Morais C., Sobki S., Al Sulaiman M., Al Khader A. N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol. Dial. Transplant. 14:1999;923-929.
66. Telci A., Salmayenli N., Aydin A.E., Yamaner S., Sivas A., Eldegez U. Serum lipids and apolipoprotein concentrations and plasma fibronectin concentrations in renal transplant patients. Eur. J. Clin. Chem. Clin. Biochem. 30:1992;847-850.
67. van den Dorpel M.A., Ghanem H., Rischen-Vos J., Man in't Veld A.J., Jansen H., Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int. 51:1997;1608-1612.
68. Varghese Z., Fernando R.L., Turakhia G., Psimenou E., Brunton C., Fernando O.N., Davenport A., Burns A., Sweny P., Powis S.H., Moorhead J.F. Oxidizability of low-density lipoproteins from neoral and tacrolimus-treated renal transplant patients. Transplant. Proc. 30:1998;2043-2046.
69. Varghese Z., Fernando R.L., Turakhia G., Psimenou E., Fernando O.N., Sweny P., Powis S.H., Moorhead J.F. Calcineurin inhibitors enhance low-density lipoprotein oxidation in transplant patients. Kidney Int. Suppl. 71:1999;S137-S140.
70. Visner G.A., Dougall W.C., Wilson J.M., Burr I.A., Nick H.S. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. J. Biol. Chem. 265:1990;2856-2864.
71. von Schonfeld J., Weisbrod B., Muller M.K. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell. Mol. Life Sci. 53:1997;917-920.
72. Wang C., Salahudeen A.K. Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E. Kidney Int. 47:1995;927-934.
73. Wenger R.M. Cyclosporine: conformation and analogues as tools for studying its mechanism of action. Transplant. Proc. 20:1988;313-318.
74. Wilkes B.M., Solomon J., Maita M., Mento P.F. Characterization of glomerular thromboxane receptor sites in the rat. Am. J. Physiol. 256:1989;F1111-F1116.
75. Wolf A., Trendelenburg C.F., Diez-Fernandez C., Prieto P., Houy S., Trommer W.E., Cordier A. Cyclosporine A-induced oxidative stress in rat hepatocytes. J. Pharmacol. Exp. Ther. 280:1997;1328-1334.
76. Yagi K. Lipid Peroxides in Biology and Medicine. 1980;Academic Press, New York.
77. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1989;1086-1095.